Outcomes of adult living donor liver transplantation: Comparison of the adult‐to‐adult living donor liver transplantation cohort study and the national experience by Olthoff, Kim M. et al.
ORIGINAL ARTICLE
Outcomes of Adult Living Donor Liver
Transplantation: Comparison of the
Adult-to-Adult Living Donor Liver Transplantation
Cohort Study and the National Experience
Kim M. Olthoff,1 Michael M. Abecassis,2 Jean C. Emond,3 Igal Kam,4 Robert M. Merion,5
Brenda W. Gillespie,6 Lan Tong,5 and the Adult-to-Adult Living Donor Liver Transplantation Cohort
Study Group
1Department of Surgery, University of Pennsylvania, Philadelphia, PA; 2Department of Surgery,
Northwestern University, Chicago, IL; 3Department of Surgery, Columbia University College of
Physicians and Surgeons, New York, NY; 4Department of Surgery, University of Colorado,
Aurora, CO; and Departments of 5Surgery and 6Biostatistics, University of Michigan,
Ann Arbor, MI
The study objectives were to determine whether the findings of the Adult-to-Adult Living Donor Liver Transplantation Cohort
Study (A2ALL) reflect the U.S. national experience and to define risk factors for patient mortality and graft loss in living do-
nor liver transplantation (LDLT). A2ALL previously identified risk factors for mortality after LDLT, which included early center
experience, older recipient age, and longer cold ischemia time. LDLT procedures at 9 A2ALL centers (n ¼ 702) and 67 non-
A2ALL centers (n ¼ 1664) from January 1998 through December 2007 in the Scientific Registry of Transplant Recipients
database were analyzed. Potential predictors of time from transplantation to death or graft failure were tested using Cox
regression. No significant difference in overall mortality between A2ALL and non-A2ALL centers was found. Higher hazard
ratios (HRs) were associated with donor age (HR ¼ 1.13 per 10 years, P ¼ 0.0002), recipient age (HR ¼ 1.20 per 10 years,
P ¼ 0.0003), serum creatinine levels (HR ¼ 1.52 per loge unit increase, P < 0.0001), hepatocellular carcinoma (HR ¼
2.12, P<0.0001) or hepatitis C virus (HR ¼ 1.18, P ¼ 0.026), intensive care unit stay (HR ¼ 2.52, P< 0.0001) or hospitali-
zation (HR ¼ 1.62, P < 0.0001) versus home, earlier center experience (LDLT case number 15: HR ¼ 1.61, P < 0.0001,
and a cold ischemia time >4.5 hours (HR ¼ 1.79, P ¼ 0.0006). Except for center experience, risk factor effects between
A2ALL and non-A2ALL centers were not significantly different. Variables associated with graft loss were identified and
showed similar trends. In conclusion, mortality and graft loss risk factors were similar in A2ALL and non-A2ALL centers.
These analyses demonstrate that findings from the A2ALL consortium are relevant to other centers in the U.S. performing
Abbreviations: A2ALL, Adult-to-Adult Living Donor Liver Transplantation Cohort Study; CI, confidence interval; CIT, cold ische-
mia time; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HR, hazard ratio; ICU, intensive care unit; LDLT, living donor
liver transplantation; MELD, Model for End-Stage Liver Disease; SD, standard deviation; SRTR, Scientific Registry of Transplant
Recipients.
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In response to the organ donor shortage, living donor
liver transplantation (LDLT) was expanded to adult
recipients, and there was rapid growth across the
United States after the first reported case in 1998.1
Limited numbers of procedures were performed at
most centers, and the approaches to the recipients
and donors were so diverse across centers that it was
difficult to provide reliable information about out-
comes that could be generalized and used for patient
education. Therefore, in 2002, the National Institutes
of Health, with supplemental funding from the Ameri-
can Society of Transplant Surgeons and the Health
Resources and Services Administration (US Depart-
ment of Health and Human Services), organized a
consortium of 9 liver transplant centers and a data
coordinating center to accrue and follow sufficient
numbers of patients being considered for and under-
going LDLT to provide results from adequately pow-
ered studies. The Adult-to-Adult Living Donor Liver
Transplantation Cohort Study (A2ALL) was developed
with the aim of providing accurate information on the
risks and benefits of adult-to-adult LDLT for both
donors and recipients. Retrospective and prospective
studies were initiated with the primary goal of provid-
ing information on donor and recipient outcomes over
the span of a decade (1998-2008). Follow-up data col-
lection was completed in 2009, and a subsequent
renewal of A2ALL with additional centers has now
been funded by the National Institutes of Health.
The first report from the 9 clinical centers in the
A2ALL consortium focused on the predictors of graft
loss after LDLT. A learning curve was identified, with
graft failure risk decreasing significantly after the first
20 adult-to-adult LDLT procedures in each center.2 In
the initial report, additional risk factors for graft fail-
ure after LDLT were also identified; these included
older recipient age and the duration of cold ischemia.
Variables that were not found to be significant
included the Model for End-Stage Liver Disease
(MELD) score, the hepatitis C virus (HCV) status, and
the donor age.
Because graft failure is only one contributor to post-
transplant mortality, it is also important to determine
whether the significant risk factors associated with
graft failure that have been identified by A2ALL also
apply to recipient mortality at A2ALL and non-A2ALL
centers. As A2ALL begins additional studies in its sec-
ond phase, it is important to analyze the first phase of
A2ALL and compare the A2ALL experience to the ex-
perience of other US centers. If the findings correlate
with outcomes at other centers, then the A2ALL
reports can be viewed as representative of national
results. Therefore, the aim of this study was to deter-
mine whether the previously reported findings con-
cerning the importance of center experience and other
predictors of outcomes in A2ALL are reflected in the
national LDLT experience.
PATIENTS AND METHODS
Data for this study were obtained from the Scientific
Registry of Transplant Recipients (SRTR) under a data
use agreement. SRTR data are sourced from national
transplant data voluntarily submitted by all transplant
centers in the United States to the Organ Procurement
and Transplantation Network, and they are supple-
mented by data from the Social Security Death Master
File to identify deaths not reported by transplant cen-
ters. The multiple-source follow-up or censoring date
was calculated as the transplant anniversary (e.g., 6
months, 1 year, or 2 years) immediately before the cur-
rent SRTR database snapshot date (August 1, 2008); a
3-month lag was allowed to ensure the completion of
forms. Graft failure was defined as the date of retrans-
plantation or death (whichever was earlier).
A comparison of A2ALL centers and non-A2ALL cen-
ters was conducted through an analysis of LDLT
recipients at 9 A2ALL centers (n ¼ 702) and 67 non-
A2ALL centers (n ¼ 1664) from January 1, 1998 to
December 31, 2007. A case number was assigned to
each LDLT procedure based on the number of adult
LDLT procedures previously performed at that center
up to that date. Cold ischemia time (CIT) was defined
as the time from donor cross-clamping to the removal
of the graft from ice. CIT data from the A2ALL retro-
spective cohort study were used to augment the data
available in the SRTR database because the latter was
missing a substantial amount of data.
Statistical Analysis
Descriptive statistics included means, ranges, stand-
ard deviations (SDs), and proportions.
Potential predictors of the time from LDLT to death
or graft failure were tested with multivariable Cox
regression models that started at the time of trans-
plantation; adjustments were made for center cluster-
ing with robust variances based on the sandwich esti-
mator. Covariate effects are reported as hazard ratios
(HRs) with 95% confidence intervals (CIs). The follow-
ing covariates were evaluated: the center type (A2ALL
versus non-A2ALL), the center-specific LDLT case
number, the transplant year (on or before December
31, 2000 versus after December 31, 2000), the recipi-
ent age, the recipient weight, the donor age, the do-
nor weight, diagnoses of hepatocellular carcinoma
(HCC) and HCV, the presence of ascites, the pretrans-
plant status [intensive care unit (ICU), hospital (non-
ICU), or home], the CIT, the serum creatinine levels,
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and the biological relationship (biologically related versus
unrelated). A2ALL data from SRTR were augmented with
CIT data from A2ALL when they were not available from
SRTR; this was not possible for the non-A2ALL data.
Because of the level of missing CIT data in the SRTR
database, separate CIT models were fitted with the sub-
set of the cohort with complete CIT data. Statistical inter-
actions between the center type and other predictors
were tested. An assessment of the association of patient
and graft survival with the case number was performed
by the estimation of the HR by 5-case intervals (eg, cases
1-5 and cases 6-10); a case number >30 was used as the
reference category. When individual center effects were
added to the models with indicator variables, the vari-
ability in mortality among the centers was statistically
significant (P < 0.001), even when it was limited to cen-
ters withmore than 10 LDLT cases (P< 0.001); this moti-
vated us to adjust the analysis for center clustering. P
values 0.05 were considered to be statistically signifi-
cant. All analyses were carried out with SAS 9.2 statisti-
cal software (SAS Institute, Inc., Cary, NC).
Protection of Human Subjects
The study was approved by the institutional review
boards and privacy boards of the University of Michi-




The characteristics of patients from A2ALL and non-
A2ALL centers are shown in Table 1. The mean donor
and recipient ages were similar for the A2ALL and
non-A2ALL centers. The A2ALL centers reported
higher mean MELD scores and a higher percentage of
recipients with HCV. A2ALL centers also had a higher
percentage of left lobe recipients, but this percentage
was very small in both types of centers (5% versus
4%). The overall mean creatinine levels were not dif-
ferent, but a significantly higher percentage of non-
A2ALL patients had serum creatinine levels 0.7 mg/
dL. The non-A2ALL group also had higher percentages
of HCC patients and patients in the ICU or hospital.
LDLT grafts at A2ALL centers had a significantly
shorter mean CIT. Because most non-A2ALL centers
never exceeded 15 LDLT cases in all, the proportion of
recipient case numbers 15 was significantly higher
in this group (33% versus 19%, P < 0.001).
Transplant Centers and Volume
In all, 2366 LDLT procedures, including 702 (30%) at
the 9 A2ALL centers and 1664 (70%) at 67 non-A2ALL
centers, were performed during the study period.
Approximately two-thirds (42/67) of the non-A2ALL
TABLE 1. Characteristics of the Liver Transplant Recipients in the A2ALL and Non-A2ALL Centers
Characteristic
A2ALL Centers (n ¼ 9) Non-A2ALL Centers (n ¼ 67)
P Value*n Range Mean (SD) or % n Range Mean (SD) or %
Recipient age (years) 702 18-73 50.1 (10.9) 1664 18-78 50.6 (11.6) 0.38
Donor age (years) 702 18-65 37.1 (10) 1663 16-73 37.2 (10.8) 0.89
Recipient weight (kg)† 609 51-107 76.7 (17.3) 1582 51-107 77.6 (17.4) 0.26
Recipient MELD score 471 6-40 14.9 (5.7) 1190 6-40 14.2 (5.3) 0.02
Serum creatinine (mg/dL) 681 0.1-6.6 1.0 (0.5) 1639 0.1-11.2 1.0 (0.7) 0.26
0 to 0.7 181 27 532 33 0.004
>0.7 to 0.9 193 28 486 29
>0.9 to 1.1 140 21 257 16
>1.1 167 24 364 22
Diagnosis of HCV 296 42 579 35 0.0007
Diagnosis of HCC 38 5 133 8 0.03
Left lobe recipient (2004-2007) 12/249 5 28/709 4 0.005
Recipient medical condition <0.0001
Home 624 89 1363 82
Hospitalization (no ICU) 55 8 238 14
ICU 23 3 63 4
CIT (hours)‡ 517 0-12 1.6 (1.4) 990 0-12.8 1.9 (1.7) <0.001
CIT > 4.5 hours 19 4 59 6 0.06
Recipient case number  15§ 132 19 543 33 <0.001
NOTE: All A2ALL centers performed at least 15 LDLT procedures. Most non-A2ALL centers (42/67) performed 15 or fewer
LDLT procedures.
*The t test was used for continuous variables; the chi-square test was used for categorical variables.
†The 5th to 95th percentiles are reported instead of the range because of outliers.
‡The CIT values are supplemented by A2ALL data; CITs  13 hours are excluded.
§A case number  15 indicates LDLT cases among the first 15 cases performed at a center (ie, during the period of less
center experience).
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centers performed 15 or fewer LDLT procedures over
the 10-year study period. Five non-A2ALL centers and
3 A2ALL centers each performed more than 100 LDLT
procedures. The number of years of activity (1 LDLT
procedure per year) between 1998 and 2007 varied
widely among the non-A2ALL centers (median ¼ 4
years, range ¼ 1-10 years), with only 1 of 67 pro-
grams (1.5%) active for all 10 years. In contrast, 3 of
9 A2ALL centers (33%) were active during each year
(median ¼ 9 years, range ¼ 7-10 years).
A2ALL centers were among the first to implement
LDLT programs. All 9 A2ALL centers performed their
first LDLT procedures by the end of 2000, whereas
approximately one-third of the 67 non-A2ALL centers
performed their first LDLT procedures in 2001 or later
(Fig. 1A). The distributions of LDLT procedures over
time were relatively similar between the 2 groups (Fig.
1B). However, the non-A2ALL cases reflect many cen-
ters that started and stopped, whereas the A2ALL
cases are from 9 centers that continued their activity
throughout the study period. The national trend has
been toward fewer centers performing LDLT. In 2008
and 2009, only 32 and 33 adult liver transplant pro-
grams, respectively, performed LDLT in the United
States; 8 of these were A2ALL centers. A2ALL centers
performed 30% and 37% of all US LDLT procedures
in 2008 and 2009, respectively. The number of LDLT
procedures performed in the United States peaked at
411 in 2001 and gradually declined to 198 in 2007
(Fig. 1C). Although the total number of adult LDLT
procedures has continued to decline over the last 2
years in non-A2ALL centers (124 in 2008 and 106 in
2009), the A2ALL numbers slightly increased in 2008
(n ¼ 54) and 2009 (n ¼ 62).
Figure 1. (A) Year of first LDLT for A2ALL (n ¼ 9) and non-
A2ALL centers (n ¼ 67). (B) Percentage of LDLT procedures
performed by year between 1998 and 2007 in A2ALL and non-
A2ALL centers. (C) Number of LDLT procedures performed by
year between 1998 and 2007 in A2ALL and non-A2ALL centers.
Figure 2. Relative risks of (A) patient mortality and (B) graft
failure by the center LDLT case number. The reference category
was a non-A2ALL center with a case number > 30. Adjustments
were made for recipient and donor ages, HCC and HCV
diagnoses, creatinine levels, and medical conditions at
transplant; the graft failure model was also adjusted for the
recipient weight.
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Patient Mortality
The overall adjusted posttransplant mortality risk
decreased after centers gained experience. When cen-
ter experience was divided into 5-case intervals, sepa-
rate models showed that case 15 was the threshold
from higher mortality risk to lower mortality risk at
A2ALL centers, and case 10 was the threshold at non-
A2ALL centers (Fig. 2A). For subsequent analyses
combining A2ALL and non-A2ALL transplants, we
used case 15 as the threshold to differentiate earlier
center experience (cases 1-15) from later center expe-
rience (case 16 and later cases).
In comparison with later center experience, earlier
center experience was associated with significantly
higher mortality risk at both A2ALL (HR ¼ 2.24, P <
0.0001) and non-A2ALL centers (HR ¼ 1.45, P ¼
0.005; Table 2 and Fig. 3A). In comparison with non-
A2ALL centers that performed more than 15 LDLT
procedures, mortality during the early experience was
higher in both A2ALL centers (HR ¼ 1.9, P < 0.001)
and non-A2ALL centers that stopped by case 15 (HR
¼ 1.44, P < 0.001). There was no statistical difference
between A2ALL centers during the early experience
and non-A2ALL centers that never performed more
than 15 procedures (HR ¼ 1.05, P ¼ 0.80).
Additional significant predictors of mortality (both
groups combined) were identified (Table 2). Older do-
nor age (HR ¼ 1.13 per 10 years, P ¼ 0.0002), older
recipient age (HR ¼ 1.20 per 10 years, P ¼ 0.0003), a
diagnosis of HCV (HR ¼ 1.18, P ¼ 0.026), a diagnosis
of HCC (HR ¼ 2.12, P < 0.0001), higher serum creati-
nine levels (HR ¼ 1.52 per loge unit increase, P <
0.0001), the patient’s medical condition (ICU versus
home: HR ¼ 2.52, P < 0.0001; hospitalization versus
home: HR ¼ 1.62, P < 0.0001), and early center expe-
rience (case number  15 versus case number > 15:
HR ¼ 1.61, P < 0.0001) were all significantly associ-
ated with a higher mortality risk. In a subset with
available CIT data, a CIT > 4.5 hours was associated
with a significantly higher mortality risk (HR ¼ 1.79,
P ¼ 0.0006) but occurred in only 4% to 6% of the
grafts. There was no significant difference in the
patient mortality risk between the eras (on or before
December 31, 2000 versus after December 31, 2000)
after adjustments for center experience and other
covariates.
In separate analyses of A2ALL centers and non-
A2ALL centers, all associations were consistent in
direction, although there were some differences in
effect size and significance between A2ALL and non-
A2ALL centers. The patient’s medical condition was a
significant predictor of patient mortality in non-A2ALL
centers (ICU versus home: HR ¼ 2.89, P < 0.0001;
hospitalization versus home: HR ¼ 1.67, P < 0.0001)
but not in A2ALL centers. We tested for differences in
the association of each factor by center type (ie,
TABLE 2. Cox Regression Models for Patient Survival
Predictor*
A2ALL and Non-A2ALL Centers Combined A2ALL Centers Only Non-A2ALL Centers Only
HR P Value 95% CI
P Value for the
Interaction With
Center Type† HR P Value 95% CI HR P Value 95% CI
LDLT case number
15
1.61 <0.0001 1.28-2.02 0.04 2.24 <0.0001 1.71-2.94 1.45 0.005 1.12-1.87
Donor age per
10 years
1.13 0.0002 1.06-1.20 0.23 1.22 0.009 1.05-1.41 1.10 0.006 1.03-1.18
Recipient age per
10 years




1.52 <0.0001 1.26-1.83 0.48 1.78 0.001 1.28-2.46 1.45 0.0007 1.17-1.79
Diagnosis of HCV 1.18 0.026 1.02-1.37 0.57 1.24 0.20 0.89-1.72 1.15 0.09 0.98-1.35








1.62 <0.0001 1.32-1.98 0.64 1.36 0.19 0.86-2.16 1.67 <0.0001 1.32-4.14
CIT > 4.5 hours‡ 1.79 0.0006 1.28-2.50 0.34 2.15 0.006 1.24-3.73 1.77 0.010 1.15-2.73
NOTE: Adjustments were made for center clustering with robust variances.
*Variables that were tested but were not significant included the recipient’s weight, the use of dialysis, the presence of
ascites, the donor’s weight, the donor’s biological relationship to the recipient, and the transplant year.
†Interactions were tested one at a time in models including all the main effects listed as predictors in this table.
‡Results for CIT are based on separate models with a smaller sample size because of missing CIT values in 33% of cases.
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statistical interaction). The only significant interaction
occurred with center experience; this effect was signif-
icantly stronger at A2ALL centers versus non-A2ALL
centers, as reported previously (HR ¼ 2.24 versus HR
¼ 1.45, interaction P ¼ 0.04).
Graft Failure
When the center experience was divided into 5-case
intervals, the threshold from higher graft failure risk
to lower graft failure risk was identified as case 15 at
A2ALL centers and as case 10 at non-A2ALL centers
(Fig. 2B). As we did with the mortality analyses, we
used case 15 as a threshold to differentiate earlier
center experience from later center experience in mod-
els that included A2ALL and non-A2ALL centers.
A2ALL and non-A2ALL centers had similarly higher
risks of graft failure during the early experience pe-
riod (combined HR ¼ 1.61, P < 0.0001) versus the
later experience period (ie, after the completion of at
least 15 cases; Table 3 and Fig. 3B). During their
early experience, non-A2ALL centers that never per-
formed more than 15 procedures had significantly
higher graft failure rates than the non-A2ALL centers
that performed more than 15 procedures (HR ¼ 1.30,
P ¼ 0.002). This significant difference in the early ex-
perience was not seen when non-A2ALL centers that
performed 15 LDLT procedures were compared with
A2ALL centers during their early experience (HR ¼
1.23, P ¼ 0.25).
Significant predictors of graft failure (both groups
combined) were identified (Table 3). Older donor age
(HR ¼ 1.13 per 10 years, P ¼ 0.0002), a diagnosis of
HCC (HR ¼ 1.87, P < 0.0001), higher serum creati-
nine levels (HR ¼ 1.26 per loge unit increase, P ¼
0.05), the patient’s medical condition (ICU versus
home: HR ¼ 2.67, P < 0.0003; hospitalization versus
home: HR ¼ 1.49, P < 0.0001), and early center expe-
rience (case number  15 versus case number > 15:
HR ¼ 1.61, P < 0.0001) were associated with an
increased risk of graft failure. Older recipient age (P ¼
0.26), heavier recipient weight (P ¼ 0.06), and a diag-
nosis of HCV (P ¼ 0.23) were also associated with
increased graft failure and were retained in the model
for face validity, even though they were not statisti-
cally significant. In the subset with CIT data, a CIT >
4.5 hours (HR ¼ 1.49, P ¼ 0.05) was associated with
a higher graft failure risk.
In separate analyses of A2ALL and non-A2ALL cen-
ters that considered factors associated with graft fail-
ure, all associations except recipient age, recipient
weight, and hospitalization versus home were consist-
ent in direction. Older recipient age (HR ¼ 1.26 per 10
years, P ¼ 0.01), serum creatinine levels (HR ¼ 1.43,
P ¼ 0.02), and a diagnosis of HCV (HR ¼ 1.41, P ¼
0.02) were more significant predictors of graft failure
at A2ALL centers versus non-A2ALL centers. The
effect of CIT on the graft failure risk was significantly
stronger at A2ALL centers (HR ¼ 3.25, P < 0.0001)
versus non-A2ALL centers (HR ¼ 1.29, P ¼ 0.34). The
recipient’s weight (HR ¼ 1.09 per 10 kg, P ¼ 0.011)
and medical condition (ICU versus home: HR ¼ 3.12,
P < 0.0001; hospitalization versus home: HR ¼ 1.58,
P ¼ 0.0002) were significant predictors of graft failure
in non-A2ALL centers but not in A2ALL centers. We
tested for differences by the center type (ie, statistical
interactions) and found that the center type had a sig-
nificant statistical interaction only with recipient age
(P ¼ 0.03) and CIT (P ¼ 0.03).
DISCUSSION
As the transplant community continues to make
efforts to define the most appropriate role for LDLT, it
is important to identify the significant clinical risk fac-
tors associated with graft failure and recipient mortal-
ity. Within the A2ALL consortium, one of the first
observations about adult-to-adult LDLT was the sig-
nificant learning curve: improved graft survival was
found after the first 20 cases at each center.2 We have
also recently described a decrease in the incidence of
recipient and donor complications after a period of ex-
perience.3,4 Similar findings have been reported in
large single-center reports: patient and graft survival
has improved significantly after the initial center ex-
perience.5–7 Significant clinical characteristics associ-
ated with graft loss, including older recipient age and
Figure 3. (A) Patient survival and (B) graft survival by the
center type and the center case number from an adjusted model.
Adjustments were made for the mean covariate values of the
recipient (50 years) and donor ages (37 years) at transplant,
diagnoses of HCC (0.07) and HCV (0.37), log creatinine levels
(0.09), and medical conditions (0.04 for ICU admission and
0.12 for hospitalization). The graft survival model was also
adjusted for the recipient weight (77 kg).
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CIT, were also identified. With the first phase of
A2ALL completed and the second phase beginning, it
was important to determine whether the findings of
the A2ALL consortium are representative of centers
throughout the United States with respect to experi-
ence and posttransplant outcomes (specifically graft
failure and patient mortality). Equally important were
the goals of (1) identifying any significant similarities
and differences between A2ALL and non-A2ALL cen-
ters with respect to other factors affecting outcomes
that might alter the applicability of A2ALL findings to
the general pool of patients undergoing LDLT and (2)
providing evidence regarding the most appropriate
recipients of LDLT.
In this report, we have again shown an association
between center experience and both patient and graft
outcomes after LDLT in the United States. Non-A2ALL
centers that never performed more than 15 proce-
dures had significantly higher rates of graft failure
than centers that performed more procedures. After
the first 15 cases, both A2ALL and non-A2ALL centers
demonstrated significant decreases in posttransplant
mortality. Although the A2ALL centers had signifi-
cantly higher mortality rates for their first 15 cases,
the results for non-A2ALL centers improved after only
10 LDLT cases, perhaps because many non-A2ALL
centers started in later years, with experienced teams
moving from centers that had already performed
LDLT. In comparison, the compositions of surgery
and hepatology teams remained stable in most A2ALL
centers over the years.
Learning curves are often described after the intro-
duction of a new procedure, but no new complex pro-
cedures have been introduced into the field of liver
transplantation in the last 10 years except for right
lobe LDLT. Relationships between experience and out-
comes for kidney, liver, and heart transplantation
have been reported,8,9 with outcomes being better at
high-volume centers, and a strong relationship has
been reported between higher surgeon volume and
decreased morbidity and mortality with other complex
surgical procedures.10,11 Therefore, the learning curve
noted here was not unexpected because the introduc-
tion of adult-to-adult LDLT was a major technical de-
velopment from deceased donor liver transplantation.
It was equally important to determine what other
clinical factors contribute to mortality after LDLT and
whether these factors are comparable between A2ALL
and non-A2ALL centers. These findings can help cen-
ters to select the most appropriate donors and recipi-
ents for LDLT to achieve the best outcomes. For all cen-
ters, we found that older recipient age, donor age, a
TABLE 3. Cox Regression Models for Graft Survival
Predictor*
A2ALL and Non-A2ALL
Centers Combined A2ALL Centers Only Non-A2ALL Centers Only
HR P Value 95% CI
P Value for the
Interaction With
the Center Type† HR P Value 95% CI HR P Value 95% CI
LDLT case number
15
1.61 <0.0001 1.31-1.99 0.54 1.81 <0.0001 1.48-2.00 1.58 0.0008 1.21-2.06
Donor age
per 10 years
1.13 0.0002 1.06-1.21 0.15 1.22 0.005 1.06-1.40 1.10 0.005 1.03-1.18
Recipient age
per 10 years
1.05 0.26 0.96-1.16 0.03 1.26 0.01 1.05-1.52 0.99 0.81 0.92-1.07
Recipient weight
per 10 kg




1.26 0.05 1.00-1.58 0.66 1.43 0.02 1.06-1.93 1.22 0.17 0.92-1.62
Diagnosis of HCV 1.11 0.23 0.94-1.31 0.09 1.41 0.02 1.05-1.88 1.01 0.93 0.84-1.21








1.49 0.0003 1.20-1.85 0.12 0.99 0.94 0.77-1.27 1.58 0.0002 1.24-2.02
CIT > 4.5 hours‡ 1.49 0.05 0.99-2.25 0.03 3.25 <0.0001 1.79-5.90 1.29 0.34 0.77-2.14
NOTE: Adjustments were made for center clustering with robust variances.
*Variables that were tested but were not significant included the use of dialysis, the presence of ascites, the donor’s weight,
the donor’s biological relationship to the recipient, and the transplant year.
†Interactions were tested one at a time in models including all main effects listed as predictors in this table.
‡Results for CIT are based on separate models with a smaller sample size because of missing CIT values in 33% of cases.
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diagnosis of HCC, higher creatinine levels (a major com-
ponent of the MELD score), and hospitalization or ICU
admission contributed to recipient mortality. When we
explored the clinical risk factors for mortality in A2ALL
and non-A2ALL centers that were available, we found
that these risk factor effects were not significantly dif-
ferent between A2ALL and non-A2ALL centers. The sep-
arate A2ALL and non-A2ALL models gave results of
consistent direction and fairly similar magnitudes.
With respect to graft failure, we also found similar
risk factor estimates for the A2ALL and non-A2ALL
groups. When the cohorts were combined, older donor
age, a diagnosis of HCC, higher serum creatinine lev-
els, and ICU admission were all associated with a
higher risk of graft loss. There were some differences
in the effects of individual predictors between the 2
groups; recipient age and CIT were the only 2 varia-
bles for which statistically significant differences in
their effects were demonstrated between the A2ALL
and non-A2ALL cohorts. The CIT discrepancy may be
explained by the fact that we were able to supplement
missing SRTR data with A2ALL data for this field, and
although the missing CIT data in the SRTR database
may have affected the coefficient estimates, we have
previously reported that CIT is significantly associated
with various outcomes in A2ALL.2,3,12,13 It is more diffi-
cult to explain the difference in the significance of re-
cipient age in the A2ALL group versus the non-A2ALL
group. Nonetheless, each of these factors may be clini-
cally important, either alone or in combination, and
should be considered when decisions regarding donor
and recipient selection for LDLT are being made.
The A2ALL multicenter consortium was formed to
address outcomes for both donors and recipients with
detailed prospective data collection; its goal is to gen-
eralize these results to the national experience
because detailed data collection and reporting are not
feasible on a national scale. This report demonstrates
that the A2ALL study results are generally representa-
tive of national outcomes. Although incomplete data
collection and a lack of granularity in the SRTR data
may have contributed to some of the differences noted
in this study, we have shown comparability between
the groups with respect to the magnitude and direc-
tion of risk factor effects.
Limitations of this study may include missing data
and misclassification in the SRTR database for the
covariates and outcomes investigated14 and potential
secular trends not captured in the statistical model-
ing, although era effects (on or before December 31,
2000 versus after December 31, 2000) were tested.
Also, because of the limitation of variables available
in the SRTR database, we were not able to demon-
strate the comparability of A2ALL and non-A2ALL
centers for other published A2ALL results, such as
donor and recipient complications and graft size.
From the results of all US centers performing LDLT,
we have shown that gaining initial experience is im-
portant for improving survival after LDLT, regardless
of when a center starts an adult LDLT program. The
data also demonstrate a continuing decline in the
number of adult LDLT procedures performed outside
the A2ALL consortium, and this may demonstrate the
natural tendency of these procedures to gravitate to
experienced centers.
The analyses presented here support the applica-
tion of findings from the A2ALL consortium to other
centers in the United States performing LDLT. As we
embark on further studies in the second phase of
A2ALL, the goals of the A2ALL consortium are that (1)
analyses of detailed data and lessons learned will con-
tribute to future advances on a national scale, and (2)
A2ALL findings will be used to provide guidance for
center performance and clinical decision making in
the field of adult-to-adult LDLT.
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